Technology
CCSC Technology International Holdings Limited Reports Financial Results for Fiscal Year Ended March 31, 2026
Published
2 months agoon
By
HONG KONG, July 17, 2026 /PRNewswire/ — CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced its financial results for the fiscal year ended March 31, 2026.
Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, “Fiscal year 2026 demonstrated the resilience of our business and the continued strength of our core operations. During the fiscal year, gross profit increased by 1.6% to $5.1 million, with gross profit margin improving to 29.3% from 28.3% in the prior fiscal year, supported by our continued focus on cost management and operational efficiency. We also recorded encouraging growth across selected products and markets, with revenue from connectors increasing by 5.7% and revenue from Asia increasing by 4.4%.
“During the fiscal year, we advanced several strategic initiatives designed to broaden our capabilities and strengthen our market position. We launched eNaviX, our carbon footprint and energy management system for small and medium sized enterprises, expanding our offerings into carbon management and Environmental, Social and Governance (ESG) solutions. We also commenced construction of our new European supply chain management center in Merosina, Serbia, in January 2026, which is expected to be completed and ready for operational use in December 2026 and will serve as the headquarters of our European supply chain operations.
“Looking ahead, we remain focused on enhancing our product portfolio, deepening customer relationships and improving operational flexibility as we pursue sustainable growth and long-term value for our shareholders. We believe our ongoing strategic initiatives will further strengthen our market position and support the Company’s next phase of development.”
Fiscal Year Ended March 31, 2026 Financial Highlights
Revenue was $17.3 million for the fiscal year ended March 31, 2026, compared to $17.6 million for the fiscal year ended March 31, 2025.Gross profit increased by 1.6% to $5.1 million for the fiscal year ended March 31, 2026, from $5.0 million for the fiscal year ended March 31, 2025.Gross profit margin was 29.3% for the fiscal year ended March 31, 2026, increased from 28.3% for the fiscal year ended March 31, 2025.Net loss was $4.8 million for the fiscal year ended March 31, 2026, compared to $1.4 million for the fiscal year ended March 31, 2025.Basic and diluted loss per share was $1.94 for the fiscal year ended March 31, 2026, compared to $1.22 for the fiscal year ended March 31, 2025.
Fiscal Year Ended March 31, 2026 Financial Results
Revenue
Total revenue was $17.3 million for the fiscal year ended March 31, 2026, which decreased by 1.9% from $17.6 million for the fiscal year ended March 31, 2025.
The following table sets forth revenue by interconnect products:
For the fiscal years ended March 31,
Change
2026
%
2025
%
Amount
%
(Amounts expressed in U.S. dollars)
Cables and wire harnesses
$
15,986,501
92.4
$
16,385,705
92.9
$
(399,204)
(2.4)
Connectors
1,316,243
7.6
1,245,784
7.1
70,459
5.7
Total
$
17,302,744
100.0
$
17,631,489
100.0
$
(328,745)
(1.9)
Revenue generated from cables and wire harnesses decreased by 2.4%, to $16.0 million for the fiscal year ended March 31, 2026, from $16.4 million for the fiscal year ended March 31, 2025. The decrease was primarily driven by lower sales volume, which was partially offset by the increase in the overall average selling prices of the Company’s cables and wire harness products.
Revenue generated from connectors increased by 5.7%, to $1.3 million for the fiscal year ended March 31, 2026, from $1.2 million for the fiscal year ended March 31, 2025. The increase was primarily attributable to the increase in the overall average selling prices of the Company’s connectors, partially offset by a decrease in sales volume.
The following table sets forth the disaggregation of revenue by regions:
For the fiscal years ended March 31,
Change
2026
%
2025
%
Amount
%
(Amounts expressed in U.S. dollars)
Europe
$
10,572,256
61.1
$
10,991,905
62.3
$
(419,649)
(3.8)
Asia
5,573,347
32.2
5,336,247
30.3
237,100
4.4
The Americas
1,157,141
6.7
1,303,337
7.4
(146,196)
(11.2)
Total
$
17,302,744
100.0
$
17,631,489
100.0
$
(328,745)
(1.9)
Revenue generated from Europe decreased by 3.8%, to $10.6 million for the fiscal year ended March 31, 2026, from $11.0 million for the fiscal year ended March 31, 2025. The decline stemmed from modest sales decreases in Denmark and Bulgaria, which were partially offset by slight revenue growth in Hungary and the Netherlands.
Revenue generated from Asia increased by 4.4%, to $5.6 million for the fiscal year ended March 31, 2026, from $5.3 million for the fiscal year ended March 31, 2025. This increase was primarily driven by a sales increase in Mainland China of $0.7 million and a sales increase in the Association of Southeast Asian Nations, or ASEAN, of $0.1 million, and was partially offset by a sales decrease in Hong Kong, China of $0.5 million.
Revenue generated from the Americas decreased by 11.2%, to $1.2 million for the fiscal year ended March 31, 2026, from $1.3 million for the fiscal year ended March 31, 2025. This decrease was primarily due to a sales decrease in North America of $0.2 million.
Cost of Revenue
Cost of revenue decreased by 3.2%, to $12.2 million for the fiscal year ended March 31, 2026, from $12.6 million for the fiscal year ended March 31, 2025, which was generally in line with the decrease in total revenue.
Inventory costs amounted to $8.5 million for the fiscal year ended March 31, 2026, compared to $8.6 million for the fiscal year ended March 31, 2025. The decrease in the Company’s inventory costs was primarily due to an 11.9% decrease in the total sales volume from approximately 31.3 million units in the fiscal year ended March 31, 2025 to approximately 27.6 million units in the fiscal year ended March 31, 2026.
Labor costs amounted to $2.8 million for the fiscal year ended March 31, 2026, compared to $3.1 million for the fiscal year ended March 31, 2025. The decrease in labor costs was mainly attributable to lower production volumes driven by decreased sales and the Company’s efforts to reduce labor costs.
Gross Profit and Gross Margin
Gross profit increased by 1.6%, to $5.1 million for the fiscal year ended March 31, 2026, from $5.0 million for the fiscal year ended March 31, 2025.
Gross profit margin increased by 1.0%, to 29.3% for the fiscal year ended March 31, 2026, from 28.3% for the fiscal year ended March 31, 2025, primarily due to a reduction in fixed costs per unit as a result of the Company’s efforts in reducing labor costs.
Operating Expenses
Operating expenses increased by 22.6%, to $8.5 million for the fiscal year ended March 31, 2026, from $7.0 million for the fiscal year ended March 31, 2025. The expense increase was primarily due to the increase in selling expenses of $0.5 million, the increase in general and administrative expenses of $0.01 million, and the increase in research and development expenses of $1.1 million.
Net Loss
Net loss increased by 240.7%, to $4.8 million for the fiscal year ended March 31, 2026, from $1.4 million for the fiscal year ended March 31, 2025.
Basic and Diluted Loss per Share
Basic and diluted loss per share was $1.94 for the fiscal year ended March 31, 2026, compared to $1.22 for the fiscal year ended March 31, 2025.
Financial Condition
As of March 31, 2026, the Company had cash of $4.1 million, compared to $3.7 million as of March 31, 2025.
Net cash used in operating activities in the fiscal year ended March 31, 2026 was $4.5 million, compared to $1.0 million in the fiscal year ended March 31, 2025.
Net cash used in investing activities in the fiscal year ended March 31, 2026 was $1.4 million, compared to $0.9 million in the fiscal year ended March 31, 2025.
Net cash provided by financing activities in the fiscal year ended March 31, 2026 was $6.3 million, compared to net cash used in financing activities of $0.05 million in the fiscal year ended March 31, 2025.
About CCSC Technology International Holdings Limited
CCSC Technology International Holdings Limited is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces interconnect products under both Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) models for manufacturing companies that produce end products, as well as electronic manufacturing services companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue,” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Factors that could cause actual results to differ materially include, without limitation, risks and uncertainties described in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with the United States Securities and Exchange Commission on July 17, 2026, and in the Company’s other filings with the United States Securities and Exchange Commission. Investors are encouraged to review the Annual Report on Form 20-F in its entirety for a more complete discussion of the risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
For more information, please contact:
CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
CCSC TECHNOLOGY INTERNATIONAL HOLDINGS LIMITED
CONSOLIDATED BALANCE SHEETS
(Amount in U.S. dollars, except for number of shares)
As of March 31,
2026
2025
Assets
Current assets:
Cash
$
4,093,878
$
3,685,043
Restricted cash
10,227
9,413
Accounts receivable
2,831,064
2,495,301
Inventories
2,301,216
1,761,880
Prepaid expenses and other current assets
1,669,571
1,066,032
Total current assets
10,905,956
9,017,669
Non-current assets:
Property, plant and equipment, net
1,980,764
853,959
Intangible assets, net
67,537
83,906
Operating lease right-of-use assets, net
868,418
1,106,024
Finance lease right-of-use assets, net
146,732
194,478
Deferred tax assets, net
19,308
558,683
Other non-current assets, net
4,302,029
3,510,363
Total non-current assets
7,384,788
6,307,413
TOTAL ASSETS
$
18,290,744
$
15,325,082
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable
$
2,781,034
$
1,819,647
Advance from customers
317,751
141,737
Accrued expenses and other current liabilities
1,472,141
1,345,210
Taxes payable
30,651
21,916
Operating lease liabilities, current
573,650
473,116
Finance lease liabilities, current
38,816
36,277
Total current liabilities
5,214,043
3,837,903
Non-current liabilities:
Operating lease liabilities, non-current
296,436
633,249
Finance lease liabilities, non-current
88,723
127,834
Total non-current liabilities
385,159
761,083
TOTAL LIABILITIES
$
5,599,202
$
4,598,986
Commitments and Contingencies (Note 16)
—
—
Shareholders’ equity
Class A ordinary shares, par value of US$0.005 per share; 49,500,000 shares
authorized; 3,413,520 and 658,125 shares issued and outstanding as of March 31,
2026 and 2025, respectively*
$
17,068
$
3,291
Class B ordinary shares, par value of US$0.005 per share; 500,000 shares authorized;
500,000 shares issued and outstanding as of March 31, 2026 and 2025, respectively*
2,500
2,500
Additional paid-in capital
11,182,908
4,855,795
Statutory reserve
813,235
813,235
Retained earnings
2,275,757
7,081,318
Accumulated other comprehensive loss
(1,599,926)
(2,030,043)
Total Shareholders’ Equity
12,691,542
10,726,096
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
$
18,290,744
$
15,325,082
*
Retrospectively restated for effect of the share consolidation completed in January 2026.
CCSC TECHNOLOGY INTERNATIONAL HOLDINGS LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Amount in U.S. dollars, except for number of shares)
For the years ended March 31,
2026
2025
2024
Net revenue
$
17,302,744
$
17,631,489
$
14,748,551
Cost of revenue
(12,238,334)
(12,647,287)
(10,825,943)
Gross profit
5,064,410
4,984,202
3,922,608
Operating expenses:
Selling expenses
(2,216,650)
(1,695,217)
(1,039,882)
General and administrative expenses
(4,606,701)
(4,601,637)
(4,134,394)
Research and development expenses
(1,699,630)
(654,039)
(594,521)
Total operating expenses
(8,522,981)
(6,950,893)
(5,768,797)
Loss from operations
(3,458,571)
(1,966,691)
(1,846,189)
Other (loss)/ income:
Foreign currency exchange (loss)/income, net
(419,431)
67,395
425,308
Financial and interest (loss)/income, net
(21,962)
10,538
67,636
Government subsidy
–
207,257
7,255
Other non-operating income/(expenses), net
55,968
534
(35,509)
Total other (loss)/ income
(385,425)
285,724
464,690
Loss before income tax expense
(3,843,996)
(1,680,967)
(1,381,499)
Income tax (expenses)/benefit
(961,565)
270,502
86,336
Net loss
(4,805,561)
(1,410,465)
(1,295,163)
Other comprehensive income /(loss)
Foreign currency translation adjustment
430,117
(161,106)
(523,250)
Total comprehensive loss
$
(4,375,444)
$
(1,571,571)
$
(1,818,413)
Loss per share
Basic and Diluted*
$
(1.94)
$
(1.22)
$
(1.26)
Weighted average number of ordinary shares
Basic and Diluted*
2,480,584
1,158,125
1,028,852
*
Retrospectively restated for effect of the share consolidation completed in January 2026. The EPS amounts pertain
to each class of common stock are the same.
CCSC TECHNOLOGY INTERNATIONAL HOLDINGS LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amount in U.S. dollars, except for number of shares)
For the years ended March 31,
2026
2025
2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$
(4,805,561)
$
(1,410,465)
$
(1,295,163)
Adjustments to reconcile net loss to net cash used in operating activities:
Inventory write-downs
68,783
128,241
188,268
Depreciation and amortization
216,722
238,599
238,757
Amortization of right-of-use assets
588,969
519,426
509,086
Loss from disposal of property, plant and equipment
7,802
10,889
2,188
Deferred tax expense/(benefit)
545,390
(270,502)
(249,892)
Foreign currency exchange losses/(gains)
360,960
(56,479)
(227,691)
Changes in operating assets and liabilities:
Accounts receivable
(330,965)
267,028
(500,747)
Inventories
(543,130)
130,289
(101,220)
Prepaid expenses and other current assets
(542,610)
412,124
(704,610)
Other non-current assets
(63,336)
257,086
(77,220)
Accounts payable
870,609
(359,764)
563,226
Advance from customers
177,602
(66,537)
22,060
Taxes payable
7,096
(2,971)
(340,992)
Accrued expenses and other current liabilities
(535,246)
(234,550)
(64,258)
Operating lease liabilities
(540,332)
(534,472)
(490,319)
Financing lease liabilities
9,272
3,250
24
Net cash used in operating activities
(4,507,975)
(968,808)
(2,528,503)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment
(859,118)
(327,801)
(156,999)
Prepayment of equipment and mold model
–
–
(3,639,312)
Proceed from disposal of property, plant and equipment
4,118
943
–
Purchase of land
–
(519,895)
–
Purchase of intangible asset
(568,864)
(43,737)
(29,476)
Net cash used in investing activities
(1,423,864)
(890,490)
(3,825,787)
CASH FLOWS FORM FINANCING ACTIVITIES
Repayments of long-term bank loans
–
–
(39,853)
Proceeds from issuance of ordinary shares, net of issuance cost
6,340,890
–
4,665,444
Capital contribution by shareholder
–
–
5,000
Payment made for principal portion of financing lease liabilities
(45,580)
(49,345)
(4,322)
Net cash provided by/(used in) financing activities
6,295,310
(49,345)
4,626,269
Effect of exchange rate changes on cash and restricted cash
46,178
(131,648)
(254,847)
Net change in cash and restricted cash
409,649
(2,040,291)
(1,982,868)
Cash and restricted cash, beginning of the year
3,694,456
5,734,747
7,717,615
Cash and restricted cash, end of the year
$
4,104,105
$
3,694,456
$
5,734,747
SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION:
Cash paid for income tax
$
(1,740)
$
–
$
(859,882)
Cash received from income tax refund
$
40,004
$
246,771
$
–
Cash paid for interest
$
(8,771)
$
–
$
(228)
Cash paid for operating lease
$
(581,553)
$
(571,159)
$
(575,014)
Cash paid for finance lease
$
(45,580)
$
(49,345)
$
(4,322)
Supplemental disclosure of non-cash information:
Right-of-use assets obtained in exchange for operating lease liabilities
$
268,971
$
192,311
$
137,617
Purchase of intangible assets included in accrued expenses and other
liabilities
$
(5,069)
$
(43,103)
$
–
Purchase of equipment and molds included in accrued expenses and other
liabilities
$
(626,300)
$
(11,418)
$
–
Cashless exercise of warrants
$
7,894
$
–
$
–
View original content:https://www.prnewswire.com/news-releases/ccsc-technology-international-holdings-limited-reports-financial-results-for-fiscal-year-ended-march-31-2026-302828705.html
SOURCE CCSC Technology International Holdings Limited
You may like
Technology
HIT COMEDY SERIES ‘OUT LOUD AND LAUGHING’ ANNOUNCES SEASON 4 LINEUP FEATURING CHRIS SALVATORE, PAUL WAGNER, EQUALPRIDE LEADERSHIP & MORE.
Published
21 minutes agoon
September 22, 2026By
New Season Premieres September 14 Across Out Magazine’s YouTube Network, Podcast Platforms, and OutLoudAndLaughing.com
NEW YORK, Sept. 22, 2026 /PRNewswire/ — Hit comedy interview series Out Loud and Laughing today announced its highly anticipated fourth season, partnering with leading LGBTQ+ media powerhouse equalpride (parent company of Out and The Advocate) for a major cross-platform distribution expansion. Premiering September 14, 2026, Season 4 will roll out across all major podcast platforms, the official website OutLoudAndLaughing.com, social channels, and Out Magazine’s newly revamped YouTube network.
Hosted by creators Bryan Ruiz and Jon Ruiz, Season 4 expands the show’s signature mix of bold comedy, unfiltered culture conversations, and candid interviews. The upcoming season features a dynamic slate of filmed talent alongside upcoming guest appearances, including:
Daniel Reynolds, Editor-in-Chief of Out MagazineRicky Cornish, Entertainment Editor at equalprideClaybourne Elder, Actor/SingerJake Graf, Actor/ScreenwriterJudy Gold, Comedian/ActorPaul Wagner, Actor/Adult StarChris Salvatore, Actor/SingerMaria Sjödin, ActivistDan Jinks, Film Producer (American Beauty, Milk, Big Fish)
NOW BOOKING: SEASON 4 TALENT CALLOUT
As Out Loud and Laughing expands its footprint this season, the show is actively booking guests across the entire LGBTQIA+ spectrum. The platform is seeking compelling voices from entertainment, medicine, science, business, advocacy, and everyday culture makers doing groundbreaking work. Representatives and publicists looking to pitch talent for Season 4 appearances should contact [Insert Contact Email].
“We are thrilled to welcome Out Loud and Laughing into the Out family as we expand our digital video footprint,” said Mark Berryhill, CEO of equalpride. “As we relaunch Out Magazine’s YouTube platform, bringing Out Loud and Laughing on board perfectly aligns with our mission to elevate LGBTQ+ voices, foster joy, and deliver world-class entertainment alongside our trusted journalism and advocacy.”
With Out’s YouTube relaunch, audiences gain centralized access to premium video content from equalpride’s iconic portfolio—including Out, The Advocate, Out100, and Plus.
Season 4 of Out Loud and Laughing premieres September 14. Viewers can stream directly at youtube.com/outmagazine or listen wherever podcasts are available.
About equalpride
equalpride is the leading LGBTQ+-owned media company in the United States, delivering content across print, digital, streaming, and live events. Its portfolio includes iconic brands such as Out, The Advocate, Out100, Plus, and PRIDE.com, dedicated to inspiring, entertaining, and empowering the LGBTQ+ community worldwide.
About Out Loud and Laughing
Created and hosted by New York-based duo Bryan Ruiz and Jon Ruiz, Out Loud and Laughing is a celebrated comedy platform and interview show highlighting the funniest, boldest, and most vibrant voices in the LGBTQ+ community and beyond.
Media Contact & Booking Pitch Submissions: BryanAndJon@outloudandlaughing.com
PRESS CONTACT: Bryan Ruiz and Jon Ruiz | bryanandjon@outloudandlaughing.com | +1 917-981-7742
View original content to download multimedia:https://www.prnewswire.com/news-releases/hit-comedy-series-out-loud-and-laughing-announces-season-4-lineup-featuring-chris-salvatore-paul-wagner-equalpride-leadership–more-302885187.html
SOURCE Out Loud and Laughing
Technology
QC Healthcare Announces Strategic Collaboration with Sanguina to Deploy AI-Powered Blood Health Technologies Across Nationwide Healthcare Platforms
Published
21 minutes agoon
September 22, 2026By
Collaboration will integrate Sanguina‘s AI-enabled patented fingernail analysis technology into My Pediatric Doctor and My Adult Doctor, with future applications through My VA Doctor and My Oncology Doctor and across maternal health, veterans’ health, oncology, hospital systems, clinical trials, and global healthcare initiatives.
CHARLOTTE, N.C. and ATLANTA, Sept. 22, 2026 /PRNewswire/ — QC Healthcare, a national healthcare innovation company focused on transforming patient access through technology, artificial intelligence, and connected care solutions, today announced a strategic collaboration with Sanguina, an AI-powered digital health company specializing in non-invasive fingernail analysis to derive blood health insights.
Through this collaboration, QC Healthcare will integrate Sanguina‘s innovative AI-driven screening capabilities for anemia, circulation, and other blood-health risk profiles across its growing healthcare ecosystem. The initial deployment will focus on My Pediatric Doctor, a nationwide 24/7 pediatric urgent care and primary care telehealth platform, and My Adult Doctor, a national 24/7 adult urgent care and primary care platform, with future applications planned for My VA Doctor and My Oncology Doctor.
The collaboration represents a significant advancement in the shared mission of QC Healthcare and Sanguina to deliver proactive, accessible, technology-enabled healthcare by bringing advanced screening tools directly into virtual care pathways. By leveraging artificial intelligence, digital biomarkers, and accessible patient-centered technology, QC Healthcare and Sanguina aim to improve early identification of issues in blood health, enhance remote clinical decision-making, and support more personalized healthcare delivery.
Addressing Global Healthcare Challenges Through Accessible Detection and Tracking
Anemia remains one of the most common blood-related conditions worldwide, affecting an estimated 1.9 billion people. Children, adults, pregnant and postpartum women, older adults, individuals with chronic diseases, cancer patients, and frequent blood donors are among the populations that may face elevated anemia risk and associated complications.
Most people learn their hemoglobin is low only when a lab draw happens to catch it. Between appointments, both patients and their care teams have no visibility at all. Sanguina‘s technology was built to close that gap, enabling frequent or on demand and personalized anemia screenings.
Additionally, Sanguina‘s circulation technology turns a fingernail video into a second measure of blood health. The Circulation Score quantifies the time and speed at which blood returns to the fingertips after they are briefly pressed and released, digitizing a bedside assessment clinicians have long used when evaluating peripheral perfusion. In the home setting, objective circulation trends may provide useful context for telehealth evaluations and may help clinicians determine whether follow-up assessment is appropriate for patients with symptoms or conditions associated with impaired circulation, dehydration, vascular disease, diabetes, cardiovascular concerns, recovery after illness or surgery, and other acute or chronic health needs. The score is intended to support screening, monitoring, and clinical decision-making; it is not, by itself, a diagnosis or a replacement for laboratory testing, physical examination, or emergency evaluation when indicated.
Integration into QC Healthcare‘s platforms puts it into use at national scale. By incorporating AI-enabled screening capabilities into digital healthcare workflows, QC Healthcare and Sanguina anticipate that patients can be identified earlier, evaluated more efficiently, and connected with appropriate clinical pathways before conditions become more serious.
“This collaboration represents the future direction of healthcare – moving from reactive treatment toward earlier identification, informed follow-up, and prevention,” said Eric Doherty, CEO of QC Healthcare. “By combining QC Healthcare‘s nationwide virtual care ecosystem with Sanguina‘s innovative AI technology, we can help bring meaningful blood-health information into the home and connect it to licensed clinical care. That opportunity extends across the families served by My Pediatric Doctor and My Adult Doctor today, as well as pregnant and postpartum women, veterans, and people navigating cancer who may benefit from the future My VA Doctor and My Oncology Doctor platforms.”
“Telehealth medicine enables accessible care,” said Erika Tyburski, CEO and Co-Founder of Sanguina. “Our fingernail analysis technologies push the accessible model further by equipping telehealth with on-demand tools that can be used at home to help fill missing data points between clinical interactions. Working with QC Healthcare creates an opportunity to connect anemia and circulation insights with care pathways serving children, adults, pregnant and postpartum women, veterans, and oncology patients at national scale.”
The initial focus of the collaboration will include integrating anemia and circulation screening into My Pediatric Doctor and My Adult Doctor, followed by evaluation of future applications across QC Healthcare‘s expanding platform portfolio.
Pediatric and Adult Virtual Care
Across My Pediatric Doctor, a nationwide 24/7 pediatric urgent care and primary care telehealth platform, anemia is a routine concern in childhood development, nutrition, and chronic disease management – and one that ordinarily requires a lab visit to investigate. My Adult Doctor, QC Healthcare‘s national 24/7 adult platform, serves patients managing fatigue and unexplained symptoms, adults with chronic conditions requiring ongoing monitoring, women during pregnancy and after childbirth, and patients participating in preventive health evaluations. In both settings, a between-visit blood-health history can provide clinicians with added context when deciding whether laboratory testing, an in-person examination, referral, or other follow-up is warranted.
Maternal Health, Oncology, and Veterans’ Care
Pregnancy and the postpartum period are major areas of potential impact. Iron needs rise during pregnancy, and blood loss during delivery can contribute to postpartum anemia. When clinically appropriate, convenient at-home screening and trend information could help women and their care teams recognize changes sooner, support follow-up after delivery, and connect patients with confirmatory testing and treatment. QC Healthcare‘s relationship with families through My Adult Doctor and My Pediatric Doctor creates a natural bridge between maternal care and pediatric care during a period when mothers may otherwise place their own health needs behind those of a newborn. Cancer patients may experience anemia related to disease, treatment, blood loss, or nutrition, and QC Healthcare‘s planned My Oncology Doctor platform is intended to support monitoring and care coordination between oncology visits. My VA Doctor, also in development, will extend appropriate blood-health and circulation applications to veterans, including those managing chronic disease, mobility limitations, recovery needs, or barriers to in-person care.
Building a Digital Blood Health Network
The collaboration draws on capabilities both companies are assembling into a single connected care network — artificial intelligence, telehealth, digital diagnostics, remote monitoring, data analytics, clinical research, and preventive care operating as one pathway rather than seven separate services. That integration is also what makes the model portable. The infrastructure gap that keeps a rural patient from a routine blood panel is the same gap facing health organizations across much of the world, and both companies intend to pursue international deployments, working with healthcare organizations abroad to adapt the model for populations where laboratory access is thinnest, and the need is greatest.
Health Systems, Payers, and Employers
Beyond direct-to-patient virtual care, the two companies will pursue potential deployments with hospitals, health systems, employers, payers, maternal-health programs, veterans’ organizations, oncology programs, and research partners. Potential applications include remote monitoring, population health and chronic disease management, prenatal and postpartum follow-up, discharge follow-up, preventive health campaigns, and clinically guided pathways for additional evaluation.
Clinical Research and Evidence Generation
The collaboration will also support clinical validation studies, real-world evidence generation, and clinical trial recruitment and coordination, drawing on Sanguina‘s published clinical data and QC Healthcare‘s nationwide patient reach. Any expansion into new clinical uses will follow appropriate clinical validation and regulatory review.
Working with QC Healthcare and Sanguina
Health systems, payers, employers, maternal-health organizations, veterans’ organizations, oncology programs, blood collection organizations, and research partners interested in exploring deployments can contact QC Healthcare through its platform websites or Sanguina at partnerships@sanguina.ai.
About QC Healthcare
QC Healthcare is a healthcare holding and innovation company focused on building and scaling connected healthcare businesses through artificial intelligence, digital health technologies, nationwide virtual care, strategic partnerships, clinical research, and data-driven solutions.
Through its growing ecosystem – including My Pediatric Doctor and My Adult Doctor, with My VA Doctor and My Oncology Doctor in development – QC Healthcare is creating a connected model of care designed to improve access, strengthen continuity, support better-informed clinical decisions, and accelerate responsible healthcare innovation. Learn more and follow QC Healthcare on LinkedIn.
About Sanguina
Sanguina is an AI-powered digital health company focused on improving awareness, screening, tracking, and management of blood health through accessible and innovative technology solutions. The company is led by CEO and Co-Founder Erika Tyburski.
The company’s technology platform represents a new approach to leveraging artificial intelligence and digital health tools to enable and support non-invasive health measurements on demand, in remote, point-of-care and home settings. Learn more at Sanguina.com and follow Sanguina on LinkedIn.
About My Pediatric Doctor
My Pediatric Doctor provides nationwide, 24/7 pediatric urgent and primary care telehealth, giving families convenient access to experienced U.S.-based clinicians across all 50 states, Puerto Rico, and Guam. The platform accepts insurance and also supports direct-pay access. Learn more at MyPediatricDoctor.com or follow My Pediatric Doctor on LinkedIn.
About My Adult Doctor
My Adult Doctor provides nationwide, 24/7 adult urgent and primary care telehealth across all 50 states, Puerto Rico, and Guam. Its connected care model is designed to support acute needs, preventive care, chronic disease management, medication management, laboratory ordering, referrals, care coordination, and wellness services. Learn more at MyAdultDoctor.com or follow My Adult Doctor on LinkedIn.
Media Contact
QC Healthcare and My Adult Doctor: contact@MyAdultDoctor.com | My Pediatric Doctor: contact@MyPediatricDoctor.com | Sanguina: partnerships@sanguina.ai
View original content to download multimedia:https://www.prnewswire.com/news-releases/qc-healthcare-announces-strategic-collaboration-with-sanguina-to-deploy-ai-powered-blood-health-technologies-across-nationwide-healthcare-platforms-302886131.html
SOURCE QC Healthcare
Technology
LexisNexis Risk Solutions Study Finds SNAP Fraud Costs Have Reached a Five-Year High
Published
21 minutes agoon
September 22, 2026By
Agencies now incur an average of $4.29 in total costs for every $1 lost to fraud as payment accuracy, data quality and eligibility challenges continue to mount.
WASHINGTON, Sept. 22, 2026 /PRNewswire/ — LexisNexis® Risk Solutions today released its fifth annual True Cost of Fraud™ Study for SNAP Agencies and Integrated Eligibility Systems (IES), finding that state and county Supplemental Nutrition Assistance Program (SNAP) agencies now incur an average of $4.29 in total costs for every $1 in benefits lost to fraud. This average cost is the highest level reported in the study’s five-year history. The research comes as agencies face growing pressure to improve payment accuracy, protect taxpayer resources, and deliver timely benefits while implementing new federal requirements and managing increasingly complex eligibility decisions.
A nationwide survey of 150 state and county SNAP agency decision-makers found that agencies are navigating an increasingly challenging operating environment shaped by payment accuracy requirements, evolving eligibility policies, administrative resource constraints, increasingly sophisticated fraud schemes and growing expectations for faster benefit delivery.
The survey findings point to a broader challenge. Agencies are not only confronting fraud, but also balancing increasingly complex eligibility requirements, payment accuracy expectations, administrative demands, and program integrity responsibilities. States are preparing for policy changes associated with H.R. 1 that affect SNAP eligibility requirements and program administration while also working to improve payment accuracy, manage administrative resources, and ensure eligible families receive benefits on time.
Key Findings
SNAP fraud costs reached a five-year high. Agencies now incur an average of $4.29 in total costs for every $1 lost to fraud, reflecting the growing operational and financial burden of fraud on public benefit programs.Higher payment error rates carry higher costs. Agencies reporting stronger payment accuracy also reported lower fraud-related costs, highlighting the close connection between improper payments, administrative burden and program integrity.Eligibility information gaps are adding pressure to agency operations. Agencies continue to face challenges accessing the information needed to verify eligibility, support program integrity and make timely benefit decisions.Document-related threats are increasing complexity. Agencies reported growing challenges involving document authentication and manipulated documents, demonstrating the impact of increasingly sophisticated digital and AI-enabled fraud schemes.Cross-program fraud exposure continues to rise. As integrated eligibility systems expand, agencies are encountering increased fraud risk across multiple benefit programs and eligibility environments.Better data supports earlier fraud prevention. Agencies with stronger access to trusted data and fewer information gaps were significantly more successful at identifying and preventing fraud before benefits were issued.
“The real cost of fraud today extends far beyond stolen benefits,” said Haywood Talcove, Chief Executive Officer, Government, LexisNexis Risk Solutions. “Agencies are being asked to make faster, more accurate decisions, while managing increasingly sophisticated fraud schemes, rising payment integrity expectations and growing operational demands. Our study shows that success depends on more than technology alone. Agencies achieve stronger outcomes when modernization is paired with trusted identity, income and eligibility intelligence that helps caseworkers make informed decisions, reduce improper payments and protect critical benefits.”
As policymakers and agency leaders navigate evolving federal requirements, the research reinforces that payment accuracy, administrative efficiency, program integrity and timely benefit delivery are interconnected. Strengthening access to authoritative identity, income and eligibility information can help agencies make better decisions earlier, reduce administrative burden, protect taxpayer resources and preserve access for eligible families.
About the Study
The fifth annual LexisNexis Risk Solutions True Cost of Fraud™ Study for SNAP Agencies and Integrated Eligibility Systems surveyed 150 senior state and county SNAP agency decision-makers and administrators in June 2026. The study examined fraud trends, payment error rates, integrated eligibility systems, modernization, data challenges, program integrity and expected impacts of policy changes associated with H.R. 1. LexisNexis Risk Solutions was not identified as the sponsor of the research.
About LexisNexis Risk Solutions
LexisNexis® Risk Solutions harnesses the power of data and advanced analytics to provide insights that help businesses and governmental entities reduce risk and improve decisions to benefit people around the globe. We provide data and technology solutions for a wide range of industries including insurance, financial services, healthcare, and government. Headquartered in metro Atlanta, Georgia, we have offices throughout the world and are part of RELX (LSE: REL/NYSE: RELX), a global provider of information and analytics for professional and business customers. For more information, please visit www.risk.lexisnexis.com and www.relx.com.
Media Contact:
Paul Eckloff
LexisNexis Risk Solutions
Mobile: +1.202.941.6986
Paul.Eckloff@lnssi.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lexisnexis-risk-solutions-study-finds-snap-fraud-costs-have-reached-a-five-year-high-302884856.html
SOURCE LexisNexis Risk Solutions
HIT COMEDY SERIES ‘OUT LOUD AND LAUGHING’ ANNOUNCES SEASON 4 LINEUP FEATURING CHRIS SALVATORE, PAUL WAGNER, EQUALPRIDE LEADERSHIP & MORE.
QC Healthcare Announces Strategic Collaboration with Sanguina to Deploy AI-Powered Blood Health Technologies Across Nationwide Healthcare Platforms
LexisNexis Risk Solutions Study Finds SNAP Fraud Costs Have Reached a Five-Year High
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology1 day agoNew IBM CHRO Study: AI Puts Critical Thinking at the Center of Workforce Priorities
-
Technology5 days agoMagentic raises $18M to build the AI workforce for the physical world
-
Technology4 days agoPeoplevine Secures Multi-Million-Dollar Growth Investment to Accelerate AI-Powered Hospitality
-
Technology2 days ago01F Group Announces Investment in DANA, Indonesia’s Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia’s Fintech Opportunity
-
Technology4 days ago
Saturday, September 19, 2026
-
Technology4 days ago4Humanity Introduces the National Positivity Portal, Using AI to Make the Good Happening Across America Easier to See
-
Technology1 day agoMCP Is the New NDC — Is This Travel’s Shift-to-Streaming Moment?
-
Technology5 days agodtcpay Welcomes SBI Group as Strategic Investor, Extending Series A to US$25M
